Sunday, 22 July 2018 - 15:47
  • it
  • de
  • en
  • fr

Shanghai Fosun Pharmaceutical

List of likely buyers of Novartis’ Dermatology division ($2bn) takes shape

A list of likely buyers of Novartis’ US dermatology generics division, valued at an approximate $2bn, is now drawn up, Bloomberg has reported. The list includes China-based Shanghai Fosun Pharmaceutical, Apollo Global Management, CVC Capital Partners and India-based Aurobindo Pharma. …

China’s big pharma targets India

After acquiring Gland Pharma for $1bn, China-based Fosun Pharmaceutical is reportedly in advanced talks to acquire another Indian company. Fosun is now targeting Symbiotec Pharma, a company focused on steroids, which last year posted revenues of $62m. Symbiotec, subsidiary of…

Indian administration ready to block $1.3bn Fosun-Gland Pharma deal

India’s Government body Cabinet Committee on Economic Affairs, chaired by Prime Minister Narendra Modi, reportedly decided to forbid the China-based investment fund Fosun – owned by Chinese billionaire Guo Guangchang – to carry out the $1.3 billion takeover of India-based…

Fosun Pharmaceutical ready to make a bid for Stada

Reuters reported today, quoting people close to the matter, that Shanghai Fosun Pharmaceutical is about to place an offer for Stada, and possibly in Joint Venture with a buyout fund like CVC. Fosun Pharma is part of Fosun International, a…